Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | WHR1 | P49842 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24331881 | 1.00 | KMT2A (0.36) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL24331701 | 0.99 | KMT2A (0.36) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL24330080 | 0.97 | MEN1 (0.36) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL24330074 | 0.97 | KMT2A (0.36) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL24331161 | 0.95 | MEN1 (0.34) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL22015164 | 0.94 | MEN1 (0.34) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL24330332 | 0.93 | MEN1 (0.36) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL22015131 | 0.93 | MEN1 (0.33) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL24330319 | 0.93 | MEN1 (0.36) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL24330108 | 0.93 | MEN1 (0.39) | KMT2AMEN1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220123225-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2022-04-21 | — | — | US | disclosed |
| WO-2020101316-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | 엘티소재주식회사 | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220123225-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | CRY1, CYP1A1, CYP1B1 | KMT2A 794/4885MEN1 343/4885ALDH1A1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.